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ABSTRACT: In this review the structural and func-
tional imaging changes associated with the synucleino-
pathies PD, MSA, and dementias associated with Lewy
bodies are reviewed. The role of imaging for supporting
differential diagnosis, detecting subclinical disease, and
following disease progression is discussed and its
potential use for monitoring disease progression is
debated. VC 2016 International Parkinson and Movement
Disorder Society
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In both late-onset, idiopathic Parkinson’s disease
(PD) and the genetic forms associated with alpha-
synuclein (a-Syn) mutations and multiplications or
leucine-rich repeat kinase 2 (LRRK2) and glucocere-
brosidase (GBA) gene mutations, cell loss occurs in
association with abnormal a-Syn aggregation. a-Syn
fibrils are found in intraneuronal Lewy inclusion
bodies and Lewy neuritis, and this pathology targets
the dopamine cells in the SNc and midbrain tegmen-
tum, noradrenergic cells in the locus ceruleus, seroto-
nergic cells in the median raphe, and cholinergic
projections from the pedunculopontine nucleus and
nucleus basalis. The pathology is first thought to arise
in the dorsal motor nucleus of the vagus and olfactory
bulbs.1 It then ascends through the brainstem to limbic
and association cortex, and 80% of PD cases will even-
tually develop dementia (PDD) if they survive 20 years
with their disease.2 When dementia is present before or
within 1 year of parkinsonism, the condition is labeled
dementia with Lewy bodies (DLB).3 The distribution of
aggregated a-Syn as Lewy bodies (LBs) in DLB and
PDD is similar, though there is a higher prevalence of
concommitant Alzheimer’s pathology in DLB.4
MSA is another synucleinopathy associated with
parkinsonism, but, unlike PD, early autonomic failure,
falls and postural instability, and ataxia are clinical
features of this disorder. Its pathology differs from PD
and is characterized by argyrophilic cytoplasmic glial
inclusions containing aggregated a-Syn and ubiquitin
found in central white matter (WM), the SN and the
striatum, and also pontine and medullary nuclei, the
cerebellum, and the intermediolateral columns of the
spinal cord.5,6 Nearly all cases to date have been
sporadic.
Ideally, one would wish to directly image the aggre-
gated a-Syn load in the synucleinopathies, but this has
proved problematic. Given this, imaging studies have
relied on demonstrating the structural and functional
changes associated with a-Syn pathology.
MRI is able to examine water proton relaxation and
the amplitude and direction of water diffusion along
nerve fibers enabling alterations in structural connec-
tivity to be detected. It can also detect nigral and stria-
tal iron deposition and loss of nigral melanin as
altered susceptibility. Using blood-oxygen-level–
dependent (BOLD) sequences, MRI can monitor the
slow oscillatory changes in venular oxygenation in
brain regions at rest and during actions. Detection of
synchronized oscillations of venous oxygenation in dif-
ferent brain regions at rest provides evidence of their
functional connectivity, and independent attentional,
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executive, visual, motor, and default mode networks
have been identified with independent component
analysis. The connectivity of these networks becomes
disrupted in PD with and without dementia and in
MSA.
In the synucleinopathies, radiotracer-based molecu-
lar imaging approaches, such as PET and single-
photon emission computed tomography (SPECT) can
measure in vivo brain metabolism and blood flow and
detect changes in their normal patterns of regional
covariance. In addition, these modalities are able to
detect dysfunction of dopaminergic, noradrenergic,
serotonergic, and cholinergic neurotransmission and
the abnormal aggregation of beta-amyloid and tau.
Structural Imaging
MRI has been widely used to study changes in struc-
ture of the SN, striatum, brainstem, and cerebellum in
parkinsonian syndromes. Additionally, tractography
has detected early WM damage and loss of structural
connectivity.
Substantia Nigra
For a long time, the width of SNc, visualized with
T2-weighted sequences (T2W), was the only available
structural biomarker of PD.7 PD patients show lower
SNc width, proportional to their level of motor
impairment, and a lower mean signal intensity in the
SNc.8 However, T2W MRI failed to detect significant
SNc volume changes in early-stage PD. Delineation of
SNc was improved by using proton density-weighted
and short T1 inversion recovery (STIR) sequences. On
STIR images, the SNc is depicted as a well-marginated
area of gray matter (GM) signal intensity.
Increased iron deposition can be detected in brain
nuclei using sequences sensitive to local magnetic field
inhomogeneities, such as T2 and T2*. Compared to
controls, patients with PD show decreased relaxation
times (T2, T2*) and increased relaxation rates (R2,
R2*) in the SNc, putamen, and globus pallidus (GP).9
Higher R2* in the SNc and red nucleus (RN) corre-
lates with higher UPDRS scores.10,11 Over a 3-year
follow-up, a significant correlation between DR2* in
the SNc and DUPDRS was reported.12 High R2* sig-
nal was reported to be associated with dyskinesias
when found in the SNc and RN.13 However, a second
series did not detect such a relationship.14
Field-dependent R2 increases (FDRIs) are the differ-
ences in measures of tissue R2 obtained with two dif-
ferent field strengths (e.g., 1.5T and 0.5T) and reflect
the total iron contained in ferritin molecules. Early-
onset (under 60 years) PD patients showed a higher
FDRI in the SNc, SNr, putamen, and GP than age-
matched controls, which decreases with disease
duration,15 suggesting that dysregulation of iron
metabolism occurs in PD.
Recently, relaxation measurements using adiabatic
pulse sequences sensitive to molecular motion, known
as T1q and T2q, have highlighted enhanced sensitivity
of the T2q relaxation measurements when compared
to conventional T2. A significant difference between
SNc T2q values was obtained in PD patients. More-
over, PD patients showed an asymmetry of left and
right T1q and T2q in the SNc, which was not
observed in controls.16
Susceptibility-weighted imaging (SWI) utilizes R20
measurements (R205R2*-R2, where R2* refers to the
actual observed relaxation rate, and R2 refers to the
relaxation rate intrinsic to the tissue) to accurately
depict brain iron deposition. Lower levels of phase
radians in the SNc as well as in the caudate nuclei and
RN, with higher phase shift in SNc and basal ganglia
(BG), were found in PD patients, implying an
increased iron content correlating with UPDRS
scores.17,18 A heterogeneous iron content was noted
across PD patients, despite the homogeneity of their
unilateral bradykinesia, and rigidity.19 The combina-
tion of SWI and R2* has shown enhanced relaxation
and susceptibility in the SNc and anterior GP in PD
with R2*, but not SWI, values correlating with tremor
and disease duration.20
Nigrosomes are small clusters of dopaminergic cells
within the SN exhibiting calbindin D28K negativity
on immunohistochemical staining. Nigrosome-1 is
located in the posterior third of the SNc and returns a
high signal on SWI. The healthy nigrosome-1 appear-
ance as a “swallow tail” on 3T-SWI, which is lost in
PD.21 Nigrosome-1 appears as a hyperintense ovoid
area within the dorsolateral border of the otherwise
hypointense SNc on T2W*, and this also disappears
in PD patients.22 PD patients also show undulations
of the smooth lateral SNc surface adjacent to the crus
cerebri. These aspects predominated in the more
severely affected hemisphere and were not present in
healthy subjects.23
Diffusion tensor imaging (DTI) allows the tracking
of white-matter pathways by measuring the fractional
anisotropic (FA) diffusion of water molecules along
neuronal axon fibers. In fact, FA is a parameter that
relates to the presence of oriented structures, such as
axons, in fiber bundles and its reduction may be corre-
lated to fiber degeneration. DTI detects a lower FA of
water in the SNc of PD patients, reflecting a loss of
directional flow. The greatest FA reduction was
observed in the ventrolateral rostral SNc.24,25 An FA
decrease has also been reported in subcortical WM in
the supplementary motor area and postcentral somato-
sensory cortex, a possible explanation for PD-related
sensory dysfunction, such as pain, restless legs, akathi-
sia, paresthesia, and dysesthesia.25,26 However, DTI
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analysis of the whole SNc, as opposed to subregions,
failed to discriminate PD patients from controls,24
despite their higher SN volumes.27,28 Recently, a posi-
tive correlation between baseline free-water values in
the posterior SN and subsequent changes in bradyki-
nesia and Montreal Cognitive Assessment scores over
1 year was reported.29
Magnetization transfer imaging (MTI) is a nuclear
MR technique based on the exchange of magnetiza-
tion between highly mobile protons and immobile
restricted protons on macromolecules, such as myelin
or membrane lipids. MTI is able to indirectly image a
restricted hydrogen pool, bound to the macromole-
cules, and has been used in different neurodegenera-
tive disorders. A lower magnetization transfer ratio
(MTR) in the SNc in PD was found.30 This finding
was present even in early PD cases.31 The SNc MTR
values did not differ between early and advanced PD
patients and did not correlate with UPDRS scores,32,33
although one series has suggested a correspondence
between MTR changes in the SN bilaterally and H &
Y/UPDRS scores.34
Differential Findings Across
Synucleinopathies
On conventional MRI, MSA with predominant par-
kinsonian symptoms (MSA-P) exhibits putaminal atro-
phy, T2W hypointensity, and “slit-like” marginal
hyperintensities,35 whereas MSA with predominant
cerebellar symptoms (MSA-C) shows atrophy of the
lower brainstem, pons, middle cerebellar peduncles,
vermis, with pontine cruciform T2W hyperintensity.36
Pontocerebellar abnormalities are marked in MSA,
helping to distinguish this disorder from PD, but not
from PSP.37 Dorsolateral putamen loss of signal in
T2* and gradient echo sequences has a high specificity
(>0.91) for MSA, though the sensitivity is low unless
combined with the presence of a hyperintense lateral
rim in fluid-attenuated inversion recovery (FLAIR)
sequences (0.97).38
MTI can also discriminate parkinsonian syndromes
(Fig. F11). Lower MTR values in the GP and SN help
separate PD patients from those suffering from PSP
and MSA.33,39,40 MSA patients with pyramidal tract
signs have a lower MTR of the corticospinal tract
compared to controls and MSA patients without
pyramidal signs.41 Using DTI, MTI, and R2*, the
most accurate distinction between MSA, PD, and con-
trols was obtained with putamen bilateral R2* imag-
ing (sensitivity, 77.8%; specificity, 100%).39
SWI improves the sensitivity for detecting early
MSA from 25% to 75% while preserving a high speci-
ficity (91%) by detecting early nigral abnormalities.42
SWI values of the putamen and pulvinar, showing
lower iron deposition, may also help in differentiating
MSA-P from PD.43 Red nucleus hypointensity discrim-
inates PSP from MSA-P and PD, whereas putaminal
hypointensity separates PSP and MSA from PD. How-
ever, no single or combination of regions of interest
are able to accurately discriminate PSP and MSA.44
DWI has been widely investigated in parkinsonian
syndromes. Greater putaminal regional apparent diffu-
sion coefficient (rADC) has been reported in patients
with MSA-P and PSP compared to PD and con-
trols.45,46 A putamen rADC of 0.7603 10–3 mm2/sec
discriminated atypical parkinsonism from PD with
96% sensitivity and a 100% positive predictive value.
Higher rADC values in caudate, middle cerebral
peduncle (MCP), and dorsal putamen (DP) were found
in MSA-P compared to PD and controls.47,48 In partic-
ular, MCP rADC values distinguished MSA-P from
PD with 92% sensitivity and 100% specificity, more
accurately than DP rADC measurements (66.67% sen-
sitivity; 80% specificity). Putaminal trace DWI
increases correlated with MSA-P progression and with
UPDRS scores,49 whereas rADC values of MCP posi-
tively correlated with age at examination of MSA-P
patients.47
DTI reveals lower FA and higher mean diffusivity
(MD) in the MCP of MSA cases, whereas diffusivity is
increased in the decussation of the superior cerebellar
peduncles in PSP.50 Combining tract-based spatial sta-
tistics and region of interest (ROI) analyses, a signifi-
cant reduction of FA values and an increased MD in
the bilateral corticospinal tract (CST) and left anterior
thalamic radiation (ATR) has also been reported in
FIG. 1. Comparison of axial MR images passing through the basal
ganglia: (A) T1-weighted; (B) T1-weighted with magnetization transfer;
(C) FLAIR; and (D) susceptibility-weighted image obtained in 2 parkin-
sonian patients.
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MSA-P patients.51 There was a correlation between
disease duration and FA values in the left CST and
between UPDRS motor score and FA values in the
right CST. Findings of regional DTI analysis reveal
specific differences among parkinsonisms. Compared
to PD, MSA-P cases show lower FA in the body of
corpus callosum (CC), anterior corona radiate, CST,
middle and inferior cerebellar peduncles, medial lem-
niscus, and posterior limb of the internal capsule bilat-
erally. Compared to MSA, PSP cases show higher MD
in the ATR and superior cerebellar peduncle.52
In advanced clinical stages of MSA, atrophy of the
pons, cerebellum, and middle cerebellar peduncles
becomes evident.53 Atrophy of the pontocerebellar sys-
tem results in the T2W “hot-cross bun” sign.54 In
MSA, MRI can detect a reduction of anteroposterior
diameter of the midbrain, pons, and fourth ventricle,
with atrophy of the cerebellum, bulbar olive, and mid-
brain.41 MSA-C may be suspected when brainstem
volumetric decrease occurs in parallel with cerebellar
atrophy.55
DTI of nondemented PD (PDND) cases has shown a
lower FA in frontal, temporal, and occipital WM
(OWM) compared to controls. A lower FA in bilateral
posterior cingulate projections distinguished PDD
from PDND patients correlating with cognitive and
attentional performance in PD.56
Impaired cognitive performance has also been asso-
ciated with increased MD of central WM tracts. Spe-
cifically, increased MD in frontal and parietal tracts
was associated with poor performances on semantic
fluency and the executive Tower of London tasks.57
Central white matter degeneration occurs early in PD,
and its presence could predict susceptibility to later
cognitive dysfunction.
Executive dysfunction has been correlated to DTI
variations in the frontal projection fibers, the genu of
corpo callosum, and in the superior fronto-occipital
fasciculus.58 Short-term memory alterations have been
associated with DTI changes in the fornix, whereas
long-term memory deficit have been paired to DTI
abnormalities in the right anterior corona radiate.
Attention domain dysfunction has been mapped with
DTI to diffusion changes in left cingulate gyrus and
the splenium, whereas language impairment was asso-
ciated with DTI changes in the frontal connecting
WM regions.
Functional Imaging
Imaging a-Syn
Whereas a number of small molecules bind in vivo
to aggregated a-Syn, a selective imaging biomarker
has, to date, proved elusive. First, a-Syn aggregates
exist in multiple forms, only some of which may be
toxic to cells. In PD, the bulk of a-Syn exists in oligo-
meric, rather than fibrillar, form, in contrast to beta-
amyloid (Ab) in Alzheimer’s disease (AD), which is
mainly in a fibrillar state. Peptides and antibodies that
bind selectively to these a-Syn aggregates do not read-
ily cross the blood–brain barrier (BBB) when adminis-
tered intavenously. Because PET (11C, 20 minutes;
18F, 110 minutes) and SPECT (123I, 13 hours) isotopes
have only short half-lives, peptides and antibodies
radiolabeled with these nuclei do not make suitable in
vivo brain imaging agents. A number of small polyaro-
matic molecules have now been identified that cross
the BBB and bind to a-Syn fibrils. Unfortunately, these
molecules, such as BF227,59 also tend to bind to other
aggregated proteins if present, including Ab plaques.
They are also lipophilic, and so radiotracers based on
these structures yield significant nonspecific back-
ground signals. Other examples of such molecules
include 1-{6-[(2-[18F]Fluoroethyl)(methyl)amino]-2-
naphthyl} ethylidene)malononitrile, and the diphenyl-
pyrazole derivative, Anle138. 11C-BF227 PET has
been used to measure the aggregated a-Syn load in 8
cases with probable MSA (see Fig. F22).60 Mean signal
was increased by around 15% in central WM and the
C
O
L
O
R
FIG. 2. 11C-BF227 PET in a normal subject and a case of probable MSA. The MSA case increased cortical, basal ganglia, and white matter signal
reflecting a-Syn aggregates.60 DV, distribution volume.
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BG of the MSA cases, though the individual ranges
overlapped with those of healthy controls.
Pittsburgh compound B (PiB) is a neutral phenothia-
zole that binds to both Ab and a-Syn fibrils in vitro.
However, 11C-PiB uptake in vivo was normal in 2
MSA cases studied.61 Whereas 11C-BF227 PET does
not have the sensitivity or specificity to diagnose
MSA, it could, in principle, still be used to monitor
changes in a-Syn aggregant load after interventions
such as immunotherapy. Levels of other aggregated
proteins, such as Ab, would first have to be independ-
ently determined. In practice, given that in vivo deter-
minations of a-Syn aggregant load with imaging are
problematic, functional MRI (fMRI), PET, or SPECT
are currently used to study its effects on brain
function.
The Dopaminergic System
Dopamine terminal function in the synucleinopa-
thies, PD, DLB, and MSA, can be examined in vivo
with both PET and SPECT62: (1) The availability of
presynaptic dopamine transporters (DATs) to ligands
has been assessed with PET and SPECT tropane-based
radiotracers, such as 18F-CFT, 123I-FP-CIT (DaTscan),
18F-FP-CIT, 123I-beta-CIT, 123I-altropane, and 99mTc-
TRODAT, and also nontropane ligands, such as 11C-
methylphenidate and 11C-nomifensine. (2) The activity
of aromatic acid decarboxylase (AADC), the enzyme
that converts levodopa to dopamine, has been meas-
ured with 18F-dopa PET. (c) Vesicle monoamine trans-
porter binding in dopamine terminals can be detected
with PET using the dihydrotetrabenazines, 11C-DTBZ
or 18F-DTBZ (AV-133).
Early hemiparkinsonian cases with late-onset idio-
pathic PD show bilaterally reduced putamen dopami-
nergic function targeting the posterior subregion,
activity being more depressed in the putamen contralat-
eral to the affected limbs. Dopaminergic function in the
head of caudate and ventral striatum is relatively
spared. This is also the case for genetic PD associated
with LRRK263 and GBA mutations.64 PET and SPECT
are also able to detect subclinical disease in H & Y
stage 1 late-onset genetic and sporadic PD cases, evi-
denced as involvement of the “asymptomatic” putamen
contralateral to the clinically unaffected limbs.65,66 It
has been estimated that clinical parkinsonism occurs
when PD patients have lost around 50% of their poste-
rior putamen dopamine terminal function.67
11C-methylphendiate PET detected significant reduc-
tions in putamen DAT binding in two of three asymp-
tomatic carriers of the LRRK2 gene where 18F-dopa
PET was normal, suggesting that DAT loss provides a
more sensitive marker of early terminal dysfunction
than ADDC loss.63 However, 18F-dopa PET has also
detected subclinical disease in both asymptomatic
adult LRRK268 and in GBA64 cases. Additionally, 18F-
dopa PET can demonstrate adaptive changes to puta-
men dopamine terminal dysfunction, detecting internal
pallidal rises in AADC activity in early PD, which
later fall as the disease progresses.69 Forty elderly rela-
tives of PD patients who had no overt parkinsonism,
but who manifested idiopathic hyposmia on olfactory
screening, have been investigated with baseline beta-
CIT SPECT and then followed clinically. Seven of
these forty relatives showed reduced 123I-beta-CIT
uptake in one or more striatal subregions, and the 4
with lowest DAT binding subsequently converted to
clinical PD over a 2-year follow-up period.70
In DLB, putamen dopaminergic loss is more sym-
metrical than in PD and there is a greater involvement
of the head of caudate. Imaging-pathological correla-
tions have shown that FP-CIT SPECT can successfully
separate DLB from AD in life because dopaminergic
function remains intact in the latter.71 MSA cases
show a similar asymmetric loss of putamen function
to idiopathic PD, but the head of caudate tends to be
more involved. Having said this, it has not proved
possible to reliably discriminate between PD and MSA
by imaging their pattern of loss of presynaptic dopa-
minergic function.72,73
In series where clinically probable parkinsonian and
essential tremor cases have been compared, imaging
the dopamine system with PET and SPECT has been
shown to differentiate these conditions with a sensitiv-
ity and specificity greater than 90%.74,75 Given this,
an abnormal PET or SPECT scan should be valuable
for supporting a diagnosis of dopamine deficient par-
kinsonism where there is diagnostic doubt. What still
remains uncertain is whether the finding of normal
dopaminergic function with PET or SPECT fully
excludes a diagnosis of PD. The majority of patients
clinically thought to have PD, but with normal 18F-
dopa PET or DAT SPECT imaging, so-called subjects
without evidence of dopamine deficiency (SWEDDs),
generally show little clinical progression or change in
dopamine imaging findings on long-term follow-
up.76,77 The majority of SWEDDs are later reclassified
as having a benign or dystonic tremor, whereas other
diagnoses included small vessel disease and drug-
induced syndromes. Having said that, occasional
SWEDDs in the Parkinson’s Progression Markers Inia-
tive series have been observed 2 years down the line
to develop reduced striatal FP-CIT uptake (J. Seibyl,
personal communication). These cases, however, all
had baseline DAT imaging at the low end of normal.
In general, a finding of normal presynaptic dopaminer-
gic function on imaging is associated with a good
prognosis in a case of suspected PD whatever the ulti-
mate diagnosis.
Putamen dopamine D2 receptor availability may be
measured with benzamides, such as 11C-raclopride
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PET or 123I-iodobenzamide (IBZM) SPECT, and can
rise in early untreated PD because dopamine deficiency
makes more receptors available to radioligands.78 This
rise in D2 binding normalizes after chronic exposure
to L-dopa.79 In contrast, MSA is associated with loss
of putamen dopamine D2 binding resulting from
degeneration of the nucleus.80,81 This reduction, how-
ever, is mild and so does not provide a sensitive dis-
criminator of MSA from PD. In one series, 123I-IBZM
SPECT detected reduced striatal D2 binding in two
thirds of de novo parkinsonian patients who had a
negative apomorphine response and were thought to
have early MSA.82
Following Synucleinopathy
Progression
Imaging biomarkers can, in principle, be used to
objectively monitor progression of synucleinopathies
and, more important, examine the effects of putative
neuroprotective and restorative agents on their course.
A limitation is that these biomarkers give information
about only one aspect of the disease, such as levels of
dopaminergic function or glucose metabolism. Addi-
tionally, the use of such biomarkers assumes that ther-
apeutic interventions have no direct effects on the
imaging itself. This has proved to be problematic in
practice because chronic exposure to medication can
unexpectedly influence uptake and binding of imaging
agents.
Initial studies using 18F-dopa PET and DAT SPECT
reported a 5% to 12% annual decline in putamen
dopamine terminal function in early PD patients over
2 to 4 years.67,83 These, initially de novo, PD cases,
however, were all exposed to dopamine agonists and
L-dopa during the course of these series. More
recently, a similar, slower rate of decline has been
reported for agonist alone or placebo-treated cases.84
These findings suggest that exposure to L-dopa, though
not dopamine agonists, may accelerate a reduction in
DAT binding per se. If this is the case, studies deter-
mining rate of loss of dopamine terminal function
using 18F-dopa PET and DAT SPECT as biomarkers
of efficacy of potentially neuroprotective drugs may be
confounded if L-dopa is a concommitant treatment.
To date, neuroprotective studies using imaging bio-
markers have been negative. The c-Jun N-terminal
kinase inhibitor, CEP1347, the vitamin, coenzyme
Q10, that promotes mitochondrial aerobic respiration,
the neuroimmunophylline GPI1845, and the glutamate
release inhibitor, riluzole, have all failed to influence
disease progression either clinically or with imaging
measures in PD. Interestingly, CEP1347 had an unsus-
pected depressant effect on striatal beta-CIT uptake.84
Loss of striatal D2 binding can be used to follow
MSA progression. IBZM SPECT has been reported to
detect an annual 10% loss of putamen D2 availability
in one MSA series.
18F-2-fluoro-2-deoxyglucose (FDG) is taken up by
brain regions, phosphorylated by hexokinase, and the
product, FDG-P, is trapped. Its uptake thus provides a
measure of regional cerebral glucose utilization
(rCMRGlc), which primarily reflects neuronal synaptic
activity. In nondemented PD patients, covariance anal-
ysis reveals an abnormal profile of relatively increased
lentiform nucleus and reduced frontoparietal metabo-
lism.85 This has been labeled the PD-related profile
(PDRP), and its degree of expression correlates with
levels of motor disability rated with the UPDRS.
Expression of the PDRP increases with disease pro-
gression whereas successful treatment of locomotor
symptoms with either dopaminergic replacement ther-
apy or DBS acts to normalize the PDRP.86-88 18FDG-
PET studies in MSA show reduced levels of striatal,
brainstem, and cerebellar glucose metabolism, in con-
trast to PD where these are preserved.89,90 Striatal
FDG uptake correlates with disability in MSA and so,
in principle, can be used to follow progression of
MSA by monitoring the loss of striatal glucose metab-
olism over time.fMRI can also be used to track pro-
gression of PD. Using BOLD sequences to monitor
synchronization of the slow oscillatory changes in ven-
ular oxygenation at rest across brain regions the func-
tional connectivity of attentional, executive, visual,
motor, and default mode networks can be identified
with independent component analysis. Reduced atten-
tional network connectivity has been shown to corre-
late with impaired performance of Stroop and Trail
Making B tasks in PD, whereas increased default
mode connectivity correlated with impaired perform-
ance on visual perception tests.91 This disruption of
brain connectivity in PD worsens over time and poten-
tially can be used as a biomarker of disease
progression.92
Tremor and Serotonergic
Dysfunction
Serotonergic cell function can be assessed either by
measuring median raphe serotonin HT1A binding of
cell bodies in the midbrain or the availability of sero-
tonin transporters (SERT) on terminals in the brain-
stem and cortex. HT1A sites act as autoreceptors on
serotonergic cell bodies in the median raphe, but are
also found postsynaptically on pyramidal cells in the
limbic cortex. They can be detected with 11C-
WAY100635 or 18F-MPPF PET. A 25% loss of
median raphe HT1A binding has been reported in PD
with 11C-WAY100635 PET, which correlated inver-
sely with severity of rest tremor, though not with lev-
els of rigidity or bradykinesia.93 Brainstem raphe
SERT binding can be measured with 11C-DASB PET,
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123I-beta CIT, or 123 I-FP-CIT SPECT. Decreases in
raphe SERT binding have also been reported to corre-
late with tremor severity and persistence.94,95 These
findings suggest that midbrain tegmentum pathology
may be more relevant than nigrostriatal projection
loss to the etiology of PD tremor.
Mechanisms of Dementia in
Synucleinopathies
Dementia is multifactorial in PD and is associated
with the presence of cortical LB disease, concomitant
AD and small vessel pathology, and degeneration of
dopaminergic and cholinergic projections to cortical
regions. LB and AD pathology both target cortical
association areas. FDG PET detects impaired glucose
utilization in the posterior cingulate, parietal, and tem-
poral association areas, but in PDD and DLB patients,
there is significantly greater occipital hypometabolism
than in AD.96 In nondemented PD cases who develop
isolated cognitive problems, covariance analysis detects
an abnormal cognitive profile, the PD cognition-related
pattern (PDCP), which is separate from the PDRP pro-
file associated with locomotor dysfunction.97 The
PDCP is characterized by relative glucose metabolic
reductions in medial frontal and parietal association
regions and relative increases in cerebellar cortex and
dentate nuclei. Its expression in individual subjects cor-
relates with performance on neuropsychological tests of
memory and executive functioning.
11C-NMP4A and 11C-PMP PET are markers of acetyl-
choline esterase activity, so their uptake indirectly reflects
cholinergic terminal function. Nondemented PD patients
show reduced cholinergic function in parietal and occipi-
tal cortex, and levels correlate with performance on tests
of attention and learning, though not with locomotor dis-
ability.98 In PDD, cholinergic loss spreads to involve all
areas of cortex.99 Levels of cortical 11C-PMP uptake in
PD correlate with Mini–Mental State Examination
(MMSE) scores, whereas reduced thalamic cholinergic
function is associated with gait and balance disorders.
This possibly reflects loss of cholinergic projections from
the pedunculo-pontine nucleus to the thalamus.100 Inter-
estingly, in MSA, cortical cholinergic function is rela-
tively preserved, perhaps explaining the lower prevalence
of dementia. Cholinergic function, however, is reduced in
the striatum, pons, and cerebellum of MSA cases, possi-
bly contributing to their early postural instability.101
11C-PIB PET detects Ab deposition in a minority of
PDD patients, suggesting that amyloid pathology is
not the major contributor to their cognitive prob-
lems.102,103 In contrast, a majority of DLB patients,
where onset of dementia has coincided with parkin-
sonism, show increased cortical 11C-PIB signal. DLB is
therefore a dual pathology syndrome as currently clin-
ically defined explaining its aggressive nature. Interest-
ingly, nondemented PD patients who have a raised
amyloid load on 11C-PIB PET develop cognitive defi-
cits more rapidly when followed than those who are
amyloid free at baseline.104
Systemic Organ Dysfunction in
Synucleinopathies
Iodine-123-metaiodobenzylguanidine (123I-MIBG)
SPECT is a marker of adrenergic terminal function
C
O
L
O
R
FIG. 3. 11C-donepezil PET showing reduced small intestine and pancreas cholinesterase activity in a PD case.107
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and can be used to study functional integrity of car-
diac sympathetic innervation in PD. Myocardial/
mediastinal 123I-MIBG signal ratios are reduced in
over 80% of PD cases, even when cardiac autonomic
reflexes are intact.105 123I-MIBG SPECT is normal in
most MSA patients as the autonomic dysfunction
arises from loss of pre- rather than postsynaptic sym-
pathetic innervation.106
11C-donepezil PET is a marker of acetylcholine
esterase (AChE) activity in brain and systemic organs.
In PD cases, the small intestine and pancreas show a
significant reduction in 11C-donepezil standardized
uptake value (SUV; Fig. F33).107 Myocardial AchE activ-
ity in myocardium is also mildly reduced. Loss of sys-
temic 11C-donepezil uptake could reflect reduced vagal
cholinergic innervation given that the dorsal nucleus
of the vagus is targeted by LB pathology. However,
the myenteric plexus also contains AChE, and local
pathology could also contribute to the signal loss.
Conclusions
The differential diagnosis of synucleinopathies repre-
sents a challenge. Currently, no neuroimaging has the
power to diagnose PD or atypical parkinsonism, but
its findings can be highly supportive of differential
diagnoses and help highlight the differences among the
parkinsonisms. Though we are currently unable to
selectively image aggregates of a-Syn, their structural
and functional consequences can be detected. Detec-
tion of dopamine deficiency in synucleinopathies
rationalizes trials of dopaminergic medication where
diagnostic doubt exists. Detection of reduced striatal
dopaminergic function in gene carriers at risk for PD
will allow identification of cases for neuroprotective
trials. Both MRI and radiotracer-based imaging pro-
vide potential biomarkers for following progression of
synucleinopathies and assessing the efficacy of putative
neuroprotective and restorative approaches. However,
direct effects of interventions on imaging modalities
have proven to be a confound in the interpretation of
past trials, and these need to be excluded when design-
ing future studies.
Functional imaging has helped to understand the
mechanisms underlying nonmotor complications
of PD, including dementia and depression, and can
rationalize nondopaminergic therapeutic approaches.
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